Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD1 | P21728 | 4/20 | 0.44 |
| ▸ | DRD5 | P21918 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815212 | 0.78 | CYP2C19 (0.39) | MAOADRD2DRD1DRD5DRD3 | |
| SCHEMBL13184293 | 0.78 | ADRA2A (0.53) | — | |
| SCHEMBL17068027 | 0.76 | MAOA (0.48) | MAOADRD2DRD1DRD5DRD3 | |
| SCHEMBL21195922 | 0.76 | MAOA (0.48) | MAOADRD2DRD1DRD5DRD3 | |
| SCHEMBL17815390 | 0.76 | ALDH1A1 (0.44) | MAOAMAOBNOTUMKDM4E | |
| SCHEMBL17815392 | 0.75 | DRD1 (0.46) | MAOADRD2DRD1DRD5DRD3 | |
| SCHEMBL19729084 | 0.75 | SLC6A2 (0.40) | MAOADRD1MAOBNOTUMKDM4E | |
| SCHEMBL22993136 | 0.74 | SLC6A2 (0.38) | MAOADRD2DRD1DRD5DRD3 | |
| SCHEMBL13184287 | 0.74 | ADRA2A (0.53) | — | |
| SCHEMBL12909320 | 0.73 | BCL2L1 (0.46) | MAOAMAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | MAOA 3022/4885DRD2 2756/4885DRD1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.